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Abstract
Introduction: Co-infection with Hepatitis C (HCV) and HIV is common and HIV accelerates hepatic disease progression due
to HCV. However, access to HCV treatment is limited and success rates are generally poor.
Methods: We conducted a systematic review and meta-analysis to assess HCV treatment outcomes in observational cohorts.
Two databases (Medline and EMBASE) were searched using a compound search strategy for cohort studies reporting HCV
treatment outcomes (as determined by a sustained virological response, SVR) in HIV-positive patients initiating HCV
treatment for the first time.
Results: 40 studies were included for review, providing outcomes on 5339 patients from 17 countries. The pooled
proportion of patients achieving SVR was 38%. Significantly poorer outcomes were observed for patients infected with HCV
genotypes 1 or 4 (pooled SVR 24.5%), compared to genotypes 2 or 3 (pooled SVR 59.8%). The pooled proportion of patients
who discontinued treatment due to drug toxicities (reported by 33 studies) was low, at 4.3% (3.3–5.3%). Defaulting from
treatment, reported by 33 studies, was also low (5.1%, 3.5–6.6%), as was on-treatment mortality (35 studies, 0.1% (0–0.2%)).
Conclusions: These results, reported under programmatic conditions, are comparable to those reported in randomised
clinical trials, and show that although HCV treatment outcomes are generally poor in HIV co-infected patients, those
infected with HCV genotypes 2 or 3 have outcomes comparable to HIV-negative patients.
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Introduction
Co-infection with Hepatitis C (HCV) and HIV is common, and
HIV accelerates hepatic disease progression due to HCV [1]. As a
result, HCV has become a leading cause of death of people living
with HIV in Western settings [2]. Successful treatment of HCV
can improve hepatic fibrosis, reduce incidence of hepatocellular
carcinoma, reduce mortality [3,4], and has the potential to reduce
disease transmission [5]. However, a number of factors contribute
to the limited access to treatment for most of those infected
globally: a long duration of therapy with a relatively complex
system of treatment delivery, high drug costs, high toxicity of
treatment and, perhaps most importantly, relatively poor success
rates for HCV treatment in HIV/HCV co-infection.
A recent systematic review of clinical trials assessing HCV
treatment outcomes in HIV co-infected patients reported that
around 37% of patients achieve a sustained virological response
(SVR) with pegylated interferon and ribavarin, with a lower
success rate observed in patients infected with HCV genotypes 1
and 4 [6]. These outcomes are poorer than those seen in HIV
negative patients [7]. Although clinical trials are appropriate for
determining drug efficacy, outcomes may differ under program-
matic conditions where adherence to treatment, patient and
provider motivation and available resources may be limited [8].
We conducted a systematic review to assess the outcomes of HCV
treatment in HIV co-infected patients in programmatic settings.
Methods
Search Strategy and Study Selection
Our systematic review was conducted in accordance with the
criteria of the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses group [9]. Using a pre-defined protocol (File
S1) Medline and EMBASE were systematically searched from
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initial title screen was conducted by one of us (AD) with full text
articles reviewed in duplicate (AD, NF). The bibliographies of
relevant articles were also hand searched for potentially relevant
articles. Agreement on inclusion of final articles was made through
consensus by the same reviewers. No language or geographical
restriction was applied during the search, but only English
language publications were included in the final review.
All cohort studies that reported treatment outcomes for in HIV-
positive patients chronically infected with HCV and initiating
HCV treatment for the first time were reviewed. Studies were
excluded if they reported outcomes among patients with selected
co-morbidities other than HIV, such as haemophilic or transplant
patients, and if treatment outcomes involved acute HCV infection.
Randomised trials were excluded in keeping with the aim of
assessing outcomes in programmatic settings (defined as cohort
reports in health care settings where there was no randomisation
or control group comparison). In cases of potential duplication of
studies, the largest report covering the longest time period was
included and authors were contacted for clarification.
Patient and study characteristics were extracted in duplicate
(AD, KS), with third party arbitration in case of disagreement
(NF). The primary outcome was the proportion of patients
achieving a SVR, calculated on an ‘intent-to-treat’ basis with all
patients starting treatment contributing to the denominator.
Secondary outcomes included the proportion of patients achieving
a rapid virological response (RVR), defined as an undetectable
(,50 copies/mL) serum level of HCV RNA at week 4 of
treatment; discontinuation of treatment due to adverse drug
reactions; loss to care (default); and death.
Data Analysis
Point estimates and 95% confidence intervals (95% CI) were
calculated for all primary and secondary outcomes. The variance
of raw proportions was stabilised using a Freeman-Tukey type
arcsine square-root transformation [10] and proportions were then
pooled using a DerSimonian and Laird random effects model [11].
We calculated the t
2 statistic using DerSimonian and Laird’s
method of moments estimator [11] to assess between-study
heterogeneity [12]. Sources of heterogeneity were explored
through univariate subgroup analyses to assess the potential
influence of baseline liver damage, genotype, type of HCV
treatment and co-treatment with highly-active antiretroviral
therapy (HAART). All analyses were conducted using Stata
version 12 (StataCorp LP, College Station, Texas, USA), with a P-
value #0.05 considered as significant.
Results
887 articles were screened, and 103 of these were reviewed in
full (figure 1). After identification of further papers which did not
meet the inclusion criteria (e.g. studies that included retreated
patients or studies that did not report treatment outcomes in full),
we retained 77 studies for detailed review. Over half of these
studies (37) were from Spain, and after correspondence with
authors, 37 studies were excluded as partial or complete duplicate
cohorts [13–52]. The final analysis included data on 5339 patients
from 40 studies in 17 countries (Table 1).
The proportion of patients with liver damage at baseline ranged
from 12.5% to 74%. The majority of studies (36) included a mix of
HCV genotypes. Three studies (from Argentina, Spain and the
USA) were exclusively comprised of patients infected with
genotypes 1 and 4 and two studies (from Sweden and Spain)
were exclusively comprised of patients infected with genotypes 2
and 3.
HCV treatment comprised pegylated interferon and weight-
based ribavarin in most cases, and the majority of patients (84%)
received concomitant antiretroviral therapy. Liver damage was
assessed by biopsy in over half (25) of studies. One study used
fibroscan to assess liver damage, and 3 studies used a combination
of the 2 techniques. Nine studies did not assess liver damage while
the remainder of the studies (3) did not state the method used.
The proportion of patients achieving SVR ranged from 13.8%
(2.2–32.9%) to 71.9% (48.2–90.5%), with a pooled proportion of
38% (34.7–42.3%) (t
2 0.037). Three studies were ‘adherent
cohorts’ comprising only patients who completed treatment;
removing these studies from the analysis did not affect the overall
result. The result was also unaffected by a sensitivity analysis that
included all studies from Spain regardless of potential overlap
(pooled SVR 39%). The most important determinant of treatment
success was HCV genotype, with significantly poorer outcomes for
patients infected with HCV genotypes 1 or 4 (3371 patients,
pooled SVR 24.5% (95%CI 20.4–28.6%), compared to genotypes
2 or 3 (1878 patients, pooled SVR 59.8% (95%CI 47.9–71.7%).
Cohorts in which more than 50% of patients had advanced liver
fibrosis at baseline (Metavir F3 or F4 or equivalent) [53] had
poorer outcomes compared to cohorts where less than 50% of
patients had advanced liver disease (42.8%[36.7–49%] versus
34.4%[27–41.8%]). Subgroup analyses are summarized in
Figure 2.
Rapid virological response, reported by 5 studies, was achieved
by 30.9% of patients (11.2–50.8%). The pooled proportion of
patients who discontinued treatment due to drug toxicities
(reported by 33 studies) was low, at 4.3% (3.3–5.3%). Defaulting
from treatment, reported by 33 studies, was also low (5.1%, 3.5–
6.6%), as was on-treatment mortality, (35 studies, 0.1% (0–0.2%)).
Discussion
Currently, access to effective HCV treatment is limited,
particularly for those with HCV/HIV co-infection in resource-
limited settings. This is reflected in this study by the paucity of data
reoprted from such settings. Among the 40 studies assessed, only
three were from resource-limited settings (two from Brazil and one
from Argentina), and no reports were found from African
countries, including Egypt where the burden of HCV is the
highest in the world, or sub-Saharan Africa where the burden of
HIV is the highest in the world. Limited access to treatment in
resource-limited settings is in part due to the high cost of
treatment, a perception of poorer outcomes of HCV treatment in
HIV co-infected patients, and the potential difficulties associated
with adherence and drug interactions under programmatic
conditions.
Concern has recently been expressed that the relatively high
efficacy of hepatitis treatment reported in clinical trials is not
attained in subsequent effectiveness studies carried out in the
general population under programmatic conditions [54]. In
comparison to routine programmes, patients in clinical trials tend
to be more adherent to treatment, and will usually receive
treatment free of charge provided by highly motivated clinical staff
working in optimal clinical settings [55]. Nevertheless, this review
found that programmatic outcomes were in very close alignment
to a systematic review of outcomes in clinical trials, which found
that HCV treatment responses in HIV co-infected patients is lower
than those observed in HIV-negative individuals [56]. Neverthe-
less, for HIV-positive patients infected with HCV genotypes 2 or
3, treatment outcomes are very similar (SVR 60%) to those
Outcomes of Patients Co-Infected with HCV and HIV
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genotypes in programme settings (SVR 59%) [7].
Treatment completion was generally high, with few patients
discontinuing treatment due to adverse events or defaulting from
care. The use of HAART was not associated with better outcomes,
which is consistent with other studies [57,58].
We used a broad search strategy that allowed the inclusion of a
large number of studies. We restricted studies to observational
cohorts so that the expected outcomes would better reflect those
observed in programmatic settings, but this can result in
confounding. Concomitant use of medications, unreported mental
or physical problems, or ancillary health service support could all
influence treatment outcomes, but these factors were not reported
and so could not be assessed. We attempted to use multivariate
meta-regression to explore the potential influence of patient and
programme level variables to explain differences in results between
studies. However, this was restricted by inconsistent reporting
between studies, so our exploration of associations was limited to
univariate subgroup comparisons. In addition, bias may result
from studies that pre-selected patients on the basis of character-
istics that may influence treatment success, or excluded patients
with risk factors for poor adherence. Furthermore, the final
analysis only included studies published in English, which may
lead to publication bias. Only five studies, however, were excluded
Figure 1. Identification of studies for inclusion.
doi:10.1371/journal.pone.0055373.g001
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Nevertheless, this review should be taken as an indication of
outcomes and not as an exhaustive summary.
The treatment of HCV infection is likely to evolve rapidly as a
result of a dynamic drug pipeline. For example, the first HCV
protease inhibitors have just been recently approved. In the short
to medium-term, however, the majority of HIV-positive patients
living in resource-limited settings are unlikely to benefit from these
newer treatments, just as they continue to lack access to many of
the newer antiretroviral drugs for HIV that have been marketed in
the West for many years. The results of this systematic review
support the current practice of treatment in well resourced
settings, whilst serving as a reminder for the need for better
treatments. This review also highlights the need to encourage
treatment of HCV/HIV co-infected patients in resource-limited
settings to start programmes in parallel to efforts aimed at reducing
costs of current treatment and gaining access to newer, interferon
free regimens so that new advances in treatment can be rapidly
accessed by all those that need them.
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